Warm Autoimmune Hemolytic Anemia
Autoimmune hemolytic anemia (AIHA) is a rare acquired autoimmune disease. It is caused by the dysfunction in the immune system in which the immune system attacks its red blood cells considering them foreign substances.
If the hemolysis takes place at 37 °C, it is referred to as Warm autoimmune hemolytic anemia. WAIHA accounts for 60-70% of the total AIHA cases.
DelveInsight's brings another addition to its Newsletter Series, focusing on rare, life-threatening disease of the blood.
The newsletter provides a brief introduction of the indication - Warm autoimmune hemolytic anemia, its epidemiological analysis, prevalence, marketed therapies, unmet needs, and pipeline therapies in the market.
The newsletter presents the analysis of the present Warm autoimmune hemolytic anemia market scenario, key pharma companies working to drive the WAIHA market in the coming decade, key collaborations, and partnerships that are driving the market.
Download the newsletter to know more.
Subscribe and Stay in the loop.
Know more about What's covered:
- Epidemiological trends
- Treatment approaches
- Key Companies
- Pipeline drugs
- Collaborations and deals in the domain
- R&D in the field
- Top conferences
- Indication overview
- Support from International organizations
